Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 16037-16052
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16037
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16037
Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation
Cyriac Abby Philips, Shiv Kumar Sarin, Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Author contributions: Philips CA prepared the manuscript and designed the sections; Sarin SK edited the manuscript, revised the sections and prepared the final draft.
Correspondence to: Shiv Kumar Sarin, Professor, Head, Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, VasantKunj, New Delhi 110070, India. shivsarin@gmail.com
Telephone: +91-11-46300000 Fax: +91-11-26123504
Received: April 23, 2014
Revised: July 2, 2014
Accepted: July 29, 2014
Published online: November 21, 2014
Processing time: 211 Days and 0.4 Hours
Revised: July 2, 2014
Accepted: July 29, 2014
Published online: November 21, 2014
Processing time: 211 Days and 0.4 Hours
Core Tip
Core tip: This topic highlight is an exhaustive review of acute on chronic liver failure (ACLF) secondary to reactivation of chronic hepatitis B virus (HBV) infection. It sheds light on current aspects of pathogenesis and definitions of reactivation of HBV and mechanisms of liver injury in acute on chronic liver failure in the wake of virus reactivation. The importance and effects of different nucleos(t)ide analogs in ACLF has been emphasized and an algorithm for management of this distinct condition has been provided.